Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Action Needed To Prevent Post-Brexit Catastrophe In Northern Ireland

BGMA Warns That Market Could Become ‘Unviable’ Without Fresh Approach

Executive Summary

Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.

You may also be interested in...



Legal Certainty Needed On Northern Ireland, Industry Insists

A continuing lack of legal certainty continues to plague suppliers to the Northern Ireland market despite the latest proposals from the EU Commission, UK and European off-patent industry leaders Mark Samuels and Adrian van den Hoven tell Generics Bulletin.

New BGMA Chief Battles Twin Pressures Of COVID And Brexit

When Mark Samuels took over leadership of the BGMA earlier this year, he was immediately forced to grapple with the twin pressures of Brexit and the COVID-19 pandemic. However, he tells Generics Bulletin in an exclusive interview, the UK off-patent industry has succeeded in maintaining supply against this difficult backdrop and deserves a more coherent government strategy to support the sector.

Ireland’s Supply Chain Suffers Due To Brexit And Covid

Medicines for Ireland has released a report focusing on the direct impact of Brexit and COVID-19 on the medicines supply chain. The association has called for long-term plans and solutions instead of temporary fixes for issues related to delays in the import and export of medicines. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel